1. Home
  2. GKOS vs FN Comparison

GKOS vs FN Comparison

Compare GKOS & FN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • FN
  • Stock Information
  • Founded
  • GKOS 1998
  • FN 1999
  • Country
  • GKOS United States
  • FN Cayman Islands
  • Employees
  • GKOS N/A
  • FN N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • FN Telecommunications Equipment
  • Sector
  • GKOS Health Care
  • FN Utilities
  • Exchange
  • GKOS Nasdaq
  • FN Nasdaq
  • Market Cap
  • GKOS 5.8B
  • FN 10.6B
  • IPO Year
  • GKOS 2015
  • FN 2010
  • Fundamental
  • Price
  • GKOS $103.50
  • FN $292.04
  • Analyst Decision
  • GKOS Strong Buy
  • FN Buy
  • Analyst Count
  • GKOS 13
  • FN 6
  • Target Price
  • GKOS $135.15
  • FN $249.17
  • AVG Volume (30 Days)
  • GKOS 903.0K
  • FN 586.6K
  • Earning Date
  • GKOS 07-30-2025
  • FN 08-18-2025
  • Dividend Yield
  • GKOS N/A
  • FN N/A
  • EPS Growth
  • GKOS N/A
  • FN 18.98
  • EPS
  • GKOS N/A
  • FN 8.97
  • Revenue
  • GKOS $404,523,000.00
  • FN $3,262,896,000.00
  • Revenue This Year
  • GKOS $27.88
  • FN $21.16
  • Revenue Next Year
  • GKOS $27.60
  • FN $12.83
  • P/E Ratio
  • GKOS N/A
  • FN $32.85
  • Revenue Growth
  • GKOS 23.92
  • FN 17.14
  • 52 Week Low
  • GKOS $77.10
  • FN $148.55
  • 52 Week High
  • GKOS $163.71
  • FN $300.29
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 61.38
  • FN 73.46
  • Support Level
  • GKOS $100.92
  • FN $282.15
  • Resistance Level
  • GKOS $106.52
  • FN $300.06
  • Average True Range (ATR)
  • GKOS 3.30
  • FN 9.53
  • MACD
  • GKOS 0.37
  • FN 1.47
  • Stochastic Oscillator
  • GKOS 71.27
  • FN 89.96

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About FN Fabrinet

Fabrinet provides advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advanced optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advanced packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.

Share on Social Networks: